NEWS CENTER

Position:

Group Announcement

Media reports

Group News

Shi Si Pharmaceutical Partners with Zhengzhou University to Tackle the Challenge of Using Natural Medicines to Combat Liver Fibrosis.

Category:

Group Announcement

Time：2018-04-30

Liver fibrosis is an inevitable stage in the progression from chronic hepatitis to cirrhosis and liver cancer, and it also represents the last therapeutic window for halting the worsening of hepatitis. However, the pathological process of liver fibrosis is extremely complex, involving multiple organs and systems; currently, there are still no ideal drugs available in clinical practice for treating liver fibrosis. Therefore, the development of anti-liver-fibrosis drugs holds broad market potential and is of great significance. Recently, the signing ceremony for a “Class 1.1 New Drug—Innovative Anti-Liver-Fibrosis Medication” was held at Zhengzhou University. Shijiazhuang Sihua Pharmaceutical Co., Ltd. and Zhengzhou University have joined forces, leveraging their complementary resources to tackle the challenges of liver fibrosis using natural medicines, thereby accelerating the translation of innovative natural-drug therapies into practical applications and speeding up their market launch.院

Liver fibrosis is an inevitable stage in the progression from chronic hepatitis to cirrhosis and liver cancer, and it also represents the last therapeutic window for halting the deterioration of hepatitis. However, the pathological process of liver fibrosis is extremely complex, involving multiple organs and systems; currently, there is still no ideal drug available in clinical practice for treating liver fibrosis. Therefore, the development of anti-liver-fibrosis drugs holds broad market potential and is of great significance. Recently, the signing ceremony for a “Class 1.1 New Drug—Innovative Anti-Liver-Fibrosis Medication” was held at Zhengzhou University. Shijiazhuang Sihua Pharmaceutical Co., Ltd. and Zhengzhou University have joined forces, leveraging their complementary resources to tackle the challenges of liver fibrosis using natural medicines, thereby accelerating the translation of innovative natural-drug therapies into practical applications and speeding up their market launch.

Institution-Enterprise Complementarity

Boost the vitality of launching new natural medicines.

Liver fibrosis is a pathophysiological process characterized by the abnormal proliferation of connective tissue in the liver caused by various pathogenic factors. Any liver injury triggers a fibrotic response during the liver’s repair and healing process. If the underlying injurious factors persist over a long period, the fibrotic process will continue unabated, eventually progressing to cirrhosis and ultimately leading to liver failure or even liver cancer. Worldwide, there are numerous patients suffering from liver fibrosis, yet no effective therapeutic agents currently exist to reverse liver fibrosis.

Professor Dai Guifu from Zhengzhou University has led a team for more than ten years in tackling this challenge and has finally succeeded in developing a new breakthrough method—the innovative drug ADN-9. This drug is based on the natural herbal compound andrographolide and, through systematic molecular optimization and careful screening of indications, has yielded a drug molecule that demonstrates particularly remarkable efficacy in the treatment of liver fibrosis. Administered orally, ADN-9 boasts high efficiency, low toxicity, and multi-target synergistic effects, fully highlighting the therapeutic advantages of natural medicines in addressing complex diseases.

Professor Dai Guifu boasts outstanding research capabilities and has been recognized as the leader of the innovative science and technology team for “Research and Development of Anti-Infective and Anti-Tumor Drugs” in Henan Province, as well as a key expert in the major national science and technology project “Major New Drug Creation during the 13th Five-Year Plan.” To date, the research achievements of the ADN-9 project have resulted in more than twenty invention patents both domestically and internationally. Relevant data also indicate that the candidate drug ADN-9 exhibits unique biological effects and demonstrates excellent drug-likeness, supporting further in-depth research and development of ADN-9 under Category 1.1 of the chemical drug registration classification.

Mechanism Innovation

Entering a New Normal and New Pace of Development

“Relying on our strong financial resources, extensive experience in pharmaceutical R&D, and Zhengzhou University’s leading innovation and development capabilities, the innovative drug research project for combating liver fibrosis is expected to successfully pass clinical trials and soon enter the market, bringing relief from pain and suffering to a wide range of patients with liver diseases,” said Su Xuejun, General Manager of Shijiazhuang Fourth Pharmaceutical Co., Ltd.

As a well-known pharmaceutical company in China, Shisi Pharmaceutical boasts seven decades of specialized pharmaceutical expertise and established brand heritage. The company primarily engages in the research, development, manufacturing, and sale of a wide range of pharmaceutical products, with intravenous solutions being its core focus. For many consecutive years, the company has been ranked among the top 100 Chinese pharmaceutical manufacturers and has consistently been recognized as one of the top ten leading brands in China’s chemical pharmaceutical industry, particularly in the area of formulation exports.

As a national high-tech enterprise, Shisi Pharmaceutical actively focuses on and participates in the research of major innovative drugs and other key national initiatives. Over the years, the company has established high-end R&D and innovation platforms such as a National Engineering Laboratory, a Postdoctoral Research Workstation, and an Academician Workstation. It also closely collaborates with research institutions and universities on forward-looking and practical projects, continuously enhancing its R&D and innovation capabilities. In 2017, Shisi Pharmaceutical obtained 16 patents, including 11 invention patents; and filed 10 patent applications, among which 6 were invention patents. (Zhang Xiaodong, reporter for the Health News)

Keywords:

Shimen Brand Large-Capacity Injection Receives Another Award.

Shi Si Pharmaceutical’s active pharmaceutical ingredients make their debut at the Shanghai API Exhibition.

Shimen Brand Large-Capacity Injection Receives Another Award.

Shi Si Pharmaceutical’s active pharmaceutical ingredients make their debut at the Shanghai API Exhibition.